p53 Mutation and mitotic infidelity

Cancer Investigation

Volumn 18, Issue 2, 2000, Pages 148-155

  Tarapore, Pheruza ^a   Fukasawa, Kenji ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANEUPLOIDY; ARTICLE; CARCINOGENESIS; CELL CYCLE; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CYTOKINESIS; GENE MUTATION; HUMAN; KARYOTYPING; MITOSIS; PRIORITY JOURNAL; STRESS;

EID: 0034004680     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009038246     Document Type: Article

References (66)

1. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991.
2. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 351:453-456, 1991.
3. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990.
4. Srivastava S, Zou S, Pirollo K, et al: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747-749, 1990.
5. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al: A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5362, 1988.
6. Donehower LA, Harvey M, Slagle BL, et al: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221, 1992.
7. Harvey M, McArthur MJ, Montgomery CA Jr, et al: Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genet 5:225-229, 1993.
8. Jacks T, Remington L, Williams BO, et al: Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1-7, 1994.
9. Purdie CA, Harrison DJ, Peter A, et al: Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9:603-609, 1994.
10. Donehower LA, Godley LA, Aldaz CM, et al: Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 9:882-895, 1995.
11. Bouffler SD, Kemp CJ, Balmain A, et al: Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice. Cancer Res 55:3883-3889, 1995.
12. Fukasawa K, Wiener F, Vande Woude GF, et al: Genomic instability and apoptosis are frequent in p53 deficient mice. Oncogene 15:1295-1302, 1997.
13. Harvey M, Sands AT, Weiss RS, et al: In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8:2457-2467, 1993.
14. Smith ML, Fornace AJ Jr: Genomic instability and the role of p53 mutations in cancer cells. Curr Opin Oncol 7:69-75, 1995.
15. Boveri T: The Origin of Malignant Tumors, Baltimore, Williams & Wilkins, 1929.
16. Cheng KC, Loeb LA: Genomic instability and tumor progression: mechanistic considerations. Adv Cancer Res 60:121-156, 1993.
17. Weinert T, Lydall D: Cell cycle checkpoints, genetic instability and cancer. Semin Cancer Biol 4:129-140, 1993.
18. Holliday R: Chromosome error propagation and cancer. Trends Genet 5:42-45, 1989.
19. Reid BJ, Blount PL, Rubin CE, et al: Flow-cytometric and histological progression to malignancy in Barren's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 102:1212-1219, 1992.
20. Kastan MB, Onyekwere O, Sidransky D, et al: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991.
21. Kuerbitz SJ, Plunkett BS, Walsh WV, et al: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495, 1992.
22. O'Connor, PM, Jackman J, Jondle D, et al: Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53:4776-4780 1993.
23. Agarwal ML, Agarwal A, Taylor WR, et al: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92: 8493-8497, 1995.
24. Stewart N, Hicks GG, Paraskevas F, et al: Evidence for a second cell cycle block at G2/M by p53. Oncogene 10:109-115, 1995.
25. Vikhanskaya F, Erba E, D'Incalci M, et al: Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acid Res 22:1012-1017, 1994.
26. Aloni Grinstein R, Schwartz D, Rotter V: Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. EMBO J 14, 1392-1401, 1995.
27. Agarwal ML, Taylor WR, Chernov MV, et al: The p53 network. J Biol Chem 273:1-4, 1998.
28. Fan S, Smith ML, Rivet AJH, et al: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifyl-line. Cancer Res 55:1649-1654, 1995.
29. Powell SN, DeFrank JS, Connell P, et al: Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 55:1643-1648, 1995.
30. Russell KJ, Wiens LW, Galloway DA, et al: Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and competent cells. Cancer Res 55:1639-1642, 1995.
31. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
32. Harper JW, Adami GR, Wei N, et al: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993.
33. Xiong Y, Hannon GJ, Zhang H, et al: p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993.
34. Dulic V, Kaufmann WK, Wilson SJ, et al: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023, 1994.
35. Reed SI: Control of the G1/S transition. Cancer Surv 29:7-23, 1997.
36. Harper JW, Elledge SJ, Keyomarsi K et al: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387-400, 1995.
37. Nurse P: Universal control mechanism regulating onset of M-phase. Nature 344:503-508, 1990.
38. Dulic V, Stein GH, Farahi Far D, et al: Nuclear accumulation of p21cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Biol 18:546-557, 1998.
39. Niculescu AB III, Chen X, Smeets M, et al: Effects of p21cip1/ waf1 at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18:629-643, 1998.
40. Hirakawa T, Ruley HE: Rescue of cells from ras oncogene-induced growth arrest by a second, complementing, oncogene. Proc Natl Acad Sci USA 85:1519-1523, 1988.
41. Hicks GG, Egan SE, Greenberg AH, et al: Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest. Mol Cell Biol 11:1344-1352, 1991.
42. Fukasawa K, Choi T, Vande Woude GF: Mos, meiosis and cellular transformation. NATO ASI Series 99:59-71, 1996.
43. Fukasawa K, Murakami S, Blair, DG et al: Similarities between somatic cells overexpressing mos oncogene and oocytes during meiotic interphase. Cell Growth Diff 5:1093-1103, 1994.
44. Fukasawa K, Vande Woude GF: Mos overexpression in Swiss 3T3 cells induces meiotic-like alterations of the mitotic spindle. Proc Natl Acad Sci USA 92:3430-3434, 1995.
45. Fukasawa K, Vande Woude GF: Synergy between the Mos/ MAPK pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol 17:506-518, 1997.
46. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49-139, 1998.
47. Gotoh Y, Nishida E, Matsuda S, et al: In vitro effects on microtubule dynamics of purified Xenopus M-phase-activated MAP kinase. Nature 349:251-254, 1991.
48. Choi T, Fukasawa K, Zhou R et al: The Mos/MAPK pathway regulates the size and degradation of the first polar body in maturing mouse oocytes. Proc Natl Acad Sci USA 93:7032-7035, 1996.
49. Fukasawa K, Rulong S, Resau J, et al: Overexpression of mos oncogene product in Swiss 3T3 cells induces apoptosis preferentially during S-phase. Oncogene 10:1-8, 1995.
50. Di Leonardo A, Khan SH, Linke SP, et al: DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function, Cancer Res 57: 1013-1009, 1997.
51. Minn AJ, Boise LH, Thompson CB: Expression of Bc1-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev 10:2621-2631, 1996.
52. Cross SM, Sanchez CA, Morgan CA, et al: A p53-dependent mouse spindle checkpoint. Science 267:1353-1356, 1995.
53. Lanni JS, Jacks T: Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18: 1055-1064, 1998.
54. Fukasawa K, Choi T, Kuriyama R, et al: Abnormal amplification of centrosomes and genetic instability in the absence of p53. Science 271:1744-1747, 1996.
55. Bornens M: Structure and functions of isolated centrosomes. In: The Centrosome, edited by VI Kalnins, New York, Academic Press, 1992, pp. 1-43.
56. Brinkley BR: Microtubule organizing centers. Annu Rev Cell Biol 1:145-172, 1985.
57. Vandre DD, Borisy GG: The centrosome cycle in animal cells. In: Mitosis: Molecules and Mechanisms, edited by JS Hyams, BR Brinkley, San Diego, Academic Press, 1985, pp. 39-75.
58. Carroll PE, Okuda M, Horn HF, et al: Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18:1935-1944, 1999.
59. Ozbun MA, Butel JS: Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv Cancer Res 66:71-141, 1995.
60. Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 32:39-47, 1994.
61. Raybaud-Diogene H, Tetu B, Morency R, et al: p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Eur J Cancer B Oral Oncol 32B:143-149, 1996.
62. Eyfjord JE, Thorlacius S, Steinarsdottir M, et al: p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 55:646-651, 1995.
63. Momand J, Zambetti G: Mdm-2: "big brother" of p53. J Cell Biochem 64:343-352, 1997.
64. Piette J, Neel H, Marechal V: Mdm2: keeping p53 under control. Oncogene 15:1001-1010, 1997.
65. Haupt Y, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387:296-299, 1997.
66. Kubbutat MH, Jones SN, Vousden KH: Regulation of p53 stability by Mdm2. Nature 387:299-303, 1997.